product summary
Loading...
company name :
DIMA Biotechnology
product type :
protein
product name :
Human TweakR Protein, mFc Tag
catalog :
PME100463
quantity :
10 μg, 100 μg
price :
60 USD, 298 USD
more info or order :
image
image 1 :
DIMA Biotechnology PME100463 image 1
Figure 1. Human TweakR Protein, mFc Tag on SDS-PAGE under non-reducing(NR) and reducing(R) conditions.
product information
Catalog Number :
PME100463
Product Name :
Human TweakR Protein, mFc Tag
Product Type :
protein
Size :
10 μg, 100 μg
List Price :
60 USD, 298 USD
Product Description :
Recombinant human TweakR protein with C-terminal mouse Fc tag
Background :
TNFRSF12A (TNF Receptor Superfamily Member 12A) is a Protein Coding gene. Diseases associated with TNFRSF12A include Multiple Sclerosis and Stroke, Ischemic. Among its related pathways are ERK Signaling and CDK-mediated phosphorylation and removal of Cdc6.
Purity :
The purity of the protein is greater than 95% as determined by SDS-PAGE and Coomassie blue staining.
Buffer :
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 23 % trehalose is added as protectants before lyophilization.
Uses :
Research use only
Application Summary :
Immunogen,WB,Elisa
Storage :
Store at -80°C for 12 months (Avoid repeated freezing and thawing)
more info or order :
company information
DIMA Biotechnology
Wuhan institute of Biotechnology B7
Biolake No.666 Gaoxin Road
Wuhan, Hubei
info@dimabio.com
https://www.dimabio.com
0118615307149771
headquarters: China
DIMA BIOTECH LTD (DIMABIO) focuses exclusively on the pre-clinical research market of Immune Oncology. Currently, we offer functional proteins and recombinant monoclonal antibodies. Our proprietary DimAb™ technology platform can directly clone IgG gene from immunized animal, which is a technology breakthrough in monoclonal antibody development.

All DIMABIOs protein products were manufactured by using mammalian cell expression system. To analyze the function of DIMABIOs proteins, we evaluated them by paired binding test between native ligand-receptor and or the binding capacity to the therapeutic antibodies. For DimAb™ recombinant monoclonal antibodies, we focus mainly on identifying clones with flow and blocking activity.